| RGC 脑再生科技 | | | | --- | --- | --- | | 52.880↑+19.850 +60.10% 收盘价 01/07 16:00 美东 | | | | 61.500↑ 8.620 +16.30% | | 盘前价 01/08 04:22 美东 | | 三 24 24 日 9 日 | | ● 快捷交易 | | 最高价 54.900 | 开盘价 35.290 | 成交量 322.18万 | | 最低价 35.290 | 昨收价 33.030 | 成交额 1.46亿 | | 平均价 45.344 | 市盈率ITM 亏损 | 总市值 261.49亿 (…) | | 振 幅 59.37% | 市密率(静) 亏损 | 总股本 4.94亿 | | 换手率 17.48% | 市净率 5288.000 | 流通值 9.75亿 | | 52周最高 83.600 | 委 比 82.25% | 流通股 1843.3万 | | 52周最低 0.093 | 量 比 3.96 | 包 主 1股 | | 历史最高 83.600 | 股息TTM -- | | | 历史最低 0.080 | 股票率 TM -- | | ...

交易行情显示，翔宇医疗于1月5日—6日连续两个交易日涨停，其中1月6日收涨20%，收盘价为87.12元/ 股。 北京商报讯（记者 丁宁）1月6日晚间，翔宇医疗（688626）发布股票交易异常波动公告显示，公司股 票交易连续三个交易日内日收盘价格涨幅偏离值累计达到30%，根据《上海证券交易所科创板股票上市 规则》《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规 定，属于股票交易异常波动情形。 翔宇医疗表示，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅较大。公司 目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场景布局， 与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技术、产品、 渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品尚未实现规 模化销售，营收占比较小。 ...

人民财讯1月6日电，二连板翔宇医疗(688626)1月6日披露股票交易异动公告称，近期资本市场对人脑工 程、脑机接口等概念关注度较高，相关板块股价涨幅较大。公司目前主要聚焦非侵入式脑机接口技术， 覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场景布局，与当前国际上的侵入式脑机接口技术路 线存在差异。公司在脑机接口方面的投入，目前在技术、产品、渠道市场等方面形成一定的布局，但招 投标和销售等具有滞后性，截至2025年末，相关产品尚未实现规模化销售，营收占比较小。 转自：证券时报 ...

南方财经1月6日电，翔宇医疗(688626.SH)发布异动公告，近期资本市场对人脑工程、脑机接口等概念 关注度较高，相关板块股价涨幅较大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动 疗法、认知言语、吞咽等康复全场景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在 脑机接口方面的投入，目前在技术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞 后性，截至2025年末，相关产品尚未实现规模化销售，营收占比较小。 ...

每经AI快讯，12月22日，翔宇医疗(688626.SH)发布投资者关系活动记录表称，截至目前，脑机接口相 关产品产生的销售额还较小；2026年公司将预计实现脑机接口产品销售收入的快速增长。脑机接口产品 布局方面，公司已发布约14个新品，春节前有望推出接近30个新品。截至目前，公司脑机接口相关产品 已进入超500家三级甲等医院，春节前目标进入700家以上，明年目标进入全国1500家顶尖三级甲等医 院。 （文章来源：每日经济新闻） ...

Group 1 - Jiangsu University is recognized as one of the first high-level universities in the province, with a focus on historical development, technological innovation, and international cooperation [2] - The university emphasizes the importance of the "14th Five-Year Plan" period for achieving socialist modernization and encourages students to enhance their sense of responsibility and mission [2] - Jiangsu University has a distinctive educational approach that integrates engineering with agriculture, aiming to cultivate talent for national development [2] Group 2 - Huichuang Medical Company specializes in brain science research and is positioned to benefit from the strategic goal of significantly improving technological self-reliance during the "14th Five-Year Plan" [3] - The company is encouraged to explore cutting-edge technologies and contribute to public health, with support from provincial and municipal departments to address practical challenges [3] - Wode Agricultural Machinery Company is recognized for its efforts in agricultural modernization and is urged to leverage local educational and industrial resources to innovate in smart and green agricultural technologies [3]

Core Viewpoint - Daoshi Technology (300409.SZ) announced a significant investment in Brain Family Inc. through its subsidiary Hong Kong Jiana, acquiring minority equity in the company by subscribing to Pre-B round preferred shares for $30 million [1] Company Summary - Hong Kong Jiana, a subsidiary of Daoshi Technology, will invest $30 million in Brain Family Inc. to acquire minority shareholder rights [1] - Brain Family Inc. is a leading global company in brain-computer interface technology, possessing unique technological barriers and commercialization capabilities [1] - The core team of Brain Family Inc. includes members from prestigious institutions such as Harvard and MIT, and the company holds over 460 authorized patents [1] - Brain Family Inc.'s core products have received international certifications from FDA and CE, and are widely used in various fields including medical rehabilitation, educational technology, consumer health, human-computer interaction, and entertainment [1]

Group 1 - The A-share market saw a significant rise in brain-computer interface concept stocks, with notable increases including Botao Bio rising over 12%, Innovation Medical hitting the daily limit (5 consecutive days), Sanbo Brain Science increasing over 9%, Nanjing Panda up over 4%, Qisheng Technology up over 3%, and Aipeng Medical up over 2% [1] - Innovation Medical announced its investment in Bole Brain-Computer (Hangzhou) Technology Co., Ltd. (referred to as "Bole Brain-Computer") in early 2021, holding a 40% stake in the company [1] - Bole Brain-Computer focuses on the research and development of core brain-computer interface technologies and the design and production of related products, primarily applied in the medical rehabilitation field [1] - As of the announcement date, Bole Brain-Computer's products have not officially launched, with only a small number of products sold through collaborations with research institutions [1] - The operating losses for Bole Brain-Computer are projected to be 6.60 million yuan and 8.66 million yuan for 2023 and 2024, respectively [1]

Group 1 - The core viewpoint of the news is the significant rise in A-share market stocks related to brain-computer interface concepts, with notable increases in several companies' stock prices [1] - Among the companies, Botao Bio surged over 12%, Innovation Medical reached a daily limit up (5 consecutive days), Sanbo Brain Science increased over 9%, Nanjing Panda rose over 4%, Qisheng Technology gained over 3%, and Aipeng Medical went up over 2% [1] - Innovation Medical announced its investment in Bole Brain-Computer (Hangzhou) Technology Co., Ltd., holding a 40% stake, which focuses on the research and development of core brain-computer interface technologies and related product design for medical rehabilitation [1] Group 2 - As of the announcement date, Bole Brain-Computer's products have not officially launched, with only a small quantity sold through collaborations with research institutions [1] - The projected operating losses for Bole Brain-Computer are 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - Silicon Treasure Technology (300019.SZ) has stated that the company currently does not have any products applied in the brain-computer interface sector [1] Company Summary - Silicon Treasure Technology has clarified its position regarding the development of products for brain-computer interfaces, indicating no current involvement in this area [1]